Jim Simons Athenex, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.12 - $0.21 $41,275 - $72,232	343,965 Added 39.92%	1,205,528 $178,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $1.11 $262,061 - $1.21 Million	-1,091,923 Reduced 55.9%	861,563 $232,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $0.91 $299,811 - $665,434	731,247 Added 59.83%	1,953,486 $800,000
Q1 2022 May 13, 2022	BUY	$0.79 - $1.59 $245,325 - $493,757	310,539 Added 34.06%	1,222,239 $1.01 Million
Q4 2021 Feb 11, 2022	BUY	$1.36 - $2.94 $458,636 - $991,465	337,233 Added 58.7%	911,700 $1.24 Million
Q3 2021 Nov 12, 2021	BUY	$2.97 - $4.84 $1.71 Million - $2.78 Million	574,467 New	574,467 $1.73 Million
Q1 2021 May 13, 2021	SELL	$4.08 - $14.75 $691,968 - $2.5 Million	-169,600 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$11.06 - $14.01 $1.27 Million - $1.61 Million	-115,100 Reduced 40.43%	169,600 $1.88 Million
Q3 2020 Nov 13, 2020	BUY	$10.26 - $14.55 $1.51 Million - $2.14 Million	147,100 Added 106.9%	284,700 $3.45 Million
Q2 2020 Aug 13, 2020	BUY	$7.11 - $13.76 $978,336 - $1.89 Million	137,600 New	137,600 $1.89 Million
Q4 2019 Feb 13, 2020	SELL	$9.6 - $17.75 $492,480 - $910,575	-51,300 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$12.16 - $21.0 $623,808 - $1.08 Million	51,300 New	51,300 $624,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.